• L E Diamond.
• Nextran, Inc., 303B College Road East, Princeton, NJ, USA. ldiamond@nextran.com
• Expert Opin Investig Drugs. 1999 May 1;8(5):609-23.

AbstractOrgan transplantation is considered the most effective treatment for end-stage organ failure; currently it is limited by a severe worldwide shortage of human donor organs. This has led to investigation of the potential use of animals as organ donors. For a number of reasons, the pig represents the most likely organ donor candidate. Transplantation of a vascularised porcine organ into a human or non-human primate results in an immediate and dramatic rejection process, known as hyperacute rejection, which is mediated by the binding of pre-existing antibody to the porcine graft and the subsequent activation of host complement. Strategies aimed at preventing this initial rejection have been largely successful in experimental models. This has allowed attention to turn towards an understanding of the immunological barriers comprising the next phase of xenograft rejection, termed acute vascular rejection. This delayed rejection process appears to be a humoral event, and it is likely that the control of antibody synthesis will play a pivotal role in overcoming the current barrier to successful xenotransplantation.

3 keywords...

hide…